Although modern guidelines prefer intravenous over peroral iron formulations in the treatment of dialysis patients, this attitude can be changed after the emergence of newer peroral iron medications, that can provide lower adverse effects rate and higher bioavailability. Incapsulated iron formulations (ex. Fersinol z®) eventually can do the thing and their other components contributes to the antianemic effect realization. Such medication administration is prefferable in iron deficit compensation in patients with malabsorbtion, under multiple simulteneous therapies and with high risk of adverse effects development.